Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

Purpose: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also evaluated. Experimental Design: A total of 111 patients entering a palliative therapy program, who had CT images and had undergone nutritional screening, were studied. In patients for whom follow-up scans were available (n = 44), longitudinal changes in body composition were studied at a mean of 230 62 and 95 60 days prior to demise. Results: Sixty-two patients (55.9) were sarcopenic, 44 (39.6) were overweight/obese, and 18 (16.2) were both. Age 59 years (hazard ratio, 1.71; 95 confidence interval, 1.10-2.66; P = 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95 confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass index decreased from 15.5 2.5 kg/m2 to 14.5 2.0 kg/m2 (P = 0.002), and total fat mass index decreased from 7.5 2.0kg/m2 to 6.0 1.5kg/m2 (P < 0.0001) over 135 days. Conclusions: Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult condition but can be identified using CT scans. This condition is an independent adverse prognostic indicator that should be considered for stratification of patients' entering clinical trials, systemic therapy, or support care programs. (Clin Cancer Res 2009;15(22):69739)

[1]  J. Griffiths.  Malnutrition and Undernutrition , 2011 .

[2]  J. Ross,et al.  Cancer cachexia is associated with the IL10 -1082 gene promoter polymorphism in patients with gastroesophageal malignancy. , 2009, The American journal of clinical nutrition.

[3]  A. Vigano,et al.  Relationship Between Angiotensin-Converting Enzyme Gene Polymorphism and Body Composition, Functional Performance, and Blood Biomarkers in Advanced Cancer Patients , 2009, Clinical Cancer Research.

[4]  N. Stephens,et al.  Cachexia, survival and the acute phase response , 2008, Current opinion in supportive and palliative care.

[5]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[6]  Raj Padwal,et al.  Body mass index and mortality in heart failure: a meta-analysis. , 2008, American heart journal.

[7]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[8]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[9]  D. Belpomme,et al.  Overweight/obesity and cancer genesis: more than a biological link. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  P. Stenvinkel,et al.  Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. , 2007, The American journal of clinical nutrition.

[11]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[12]  Ross Carter,et al.  Evaluation of an Inflammation-Based Prognostic Score in Patients with Inoperable Pancreatic Cancer , 2006, Pancreatology.

[13]  W. Mitch,et al.  Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. , 2006, Endocrinology.

[14]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[15]  K. Fearon,et al.  Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.

[16]  M. Goggins.  Molecular markers of early pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Peter Daneryd,et al.  Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—Correlations with food intake, metabolism, exercise capacity, and hormones , 2005, Cancer.

[18]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[19]  H. Hauner,et al.  Inhibitor κB kinase is involved in the paracrine crosstalk between human fat and muscle cells , 2004, International Journal of Obesity.

[20]  A. Tjønneland,et al.  Body fat and fat-free mass and all-cause mortality. , 2004, Obesity research.

[21]  E. Holly,et al.  Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  J. Bauer,et al.  Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. , 2004, Clinical nutrition.

[23]  E. I. Mohamed,et al.  Evaluating body composition of Italian prostate cancer patients without metastases , 2003, Acta Diabetologica.

[24]  K. Courneya,et al.  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M Ferguson,et al.  Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer , 2002, European Journal of Clinical Nutrition.

[26]  V. Heinemann.  Present and future treatment of pancreatic cancer. , 2002, Seminars in oncology.

[27]  Robert Ross,et al.  Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability , 2002, Journal of the American Geriatrics Society.

[28]  B. Heitmann,et al.  Mortality associated with body fat, fat-free mass and body mass index among 60-year-old Swedish men—a 22-year follow-up. The study of men born in 1913 , 2000, International Journal of Obesity.

[29]  D. Forman,et al.  Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group. , 1998, European journal of cancer.

[30]  S B Heymsfield,et al.  Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. , 1998, Journal of applied physiology.

[31]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[32]  K. Fearon,et al.  Changes in nutritional status associated with unresectable pancreatic cancer. , 1997, British Journal of Cancer.

[33]  T. Vehmas,et al.  Measuring visceral adipose tissue content from contrast enhanced computed tomography. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[34]  J. Ross,et al.  Acute‐phase protein response and survival duration of patients with pancreatic cancer , 1995, Cancer.

[35]  T. Byers,et al.  THE VALIDITY OF SELF‐REPORTS OF PAST BODY WEIGHTS BY U.S. ADULTS , 1995, Epidemiology.

[36]  J. Gelin,et al.  Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. , 1994, Cancer research.

[37]  J. Ross,et al.  Cytokines, the Acute‐Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic Cancer , 1994, Annals of surgery.

[38]  K. Fearon,et al.  Body composition in cancer cachexia. , 1990, Infusionstherapie.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[40]  J. Norton,et al.  Body cell mass in cancer-bearing and anorexic patients. , 1987, JPEN. Journal of parenteral and enteral nutrition.

[41]  L. Sjöström,et al.  Adipose tissue volume determinations in women by computed tomography: technical considerations. , 1986, International journal of obesity.

[42]  S. Heymsfield,et al.  Tissue components of weight loss in cancer patients. A new method of study and preliminary observations , 1985, Cancer.

[43]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[44]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.